| Home Market Dynamics Macro Trends Sector Trends Company Insights AI Investing Strategies Sign Up Login |
| Currently, stocks in the health care sector show a strong performance driven by advancements in biotechnology, robust earnings from major companies, and a favorable market sentiment surrounding health-related investments. Recent discussions highlight significant activities in mergers and acquisitions, particularly among pharmaceutical giants, further reinforcing confidence in the sector. However, ongoing legal challenges faced by prominent companies, alongside trial failures reported by key players, create volatility and risk perceptions. Overall, the market remains optimistic due to innovation and strong corporate earnings despite these challenges. The price action of Health Care (XLV) sector is shaped by numerous forces, ranging from broad macroeconomic trends to company-specific performance and market structure. The trend sentiment at -0.4 is modestly bearish. The market sentiment at 0.8 is bullish. Trend sentiment measures the current trend of the stock price, and market sentiment reflects what market participants collectively think where the price will move next.There is no clear direction for XLV since trend sentiment and market sentiment are at the opposite directions. The positive sentiment force for Health Care sector is at 0.9, and the negative at -0.1 on 2026-08-04. The forces of Sentiment towards Fundamentals (2.2), Valuation Sentiment (1.8), Broad Market Trend (0.9), Option Sentiment (0.3), Market Risk Appetite (0), and Price Level Sentiment (0) will drive up the price. The forces of and Sector Price Trend (-0.4) will drive down the price. The sentiment for Broad Market Trend is calculated based on SPY trend. The sentiment for Sector Price Trend is calculated based on XLV trend. The sentiment for Option Speculation is calculated from put/call ratio. The Risk Prefrence is calculated from Bitcoin price trend. Price Level sentiment is positive when oversold, and negative when overbought. Valuation Sentiment, and Sentimentals towards Fundamentals are extracted from headlines and market commentary. All sentiment scores are normalized on a -10 - +10 scale. The price level reaches 100 at Bollinger upper band, and zero at lower band. |
Sign up to reveice Sector Rotation Notification
| XLV | ||||||||||||||||
| Date | Attention | Price | StdDev | Price Level | RSI | Hourly RSI | Change | 10 Day Trend | Trend Sentiment | Hourly Trend Sentiment | Hourly StdDev | Market Sentiment | Action | P | Fund. | News Sentiment |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-08-04 | 4%(1.9%) | 162.05 | 1.36% | 53 | 59 | 51 | -0.13% | 0.12% | -0.4 | 0.1 | 0.3% | 0.8 | Long | 55% | 2.2 | 1.5 |
| 2026-08-03 | 1%(1.4%) | 162.26 | 1.41% | 54 | 60 | 60 | -0.18% | 0.18% | 0.2 | 0.1 | 0.4% | 0.7 | Long | 55% | 2.2 | 4.2 |
| 2026-08-02 | 3%(1.3%) | 0 | 0.8 | 2.2 | 6 | |||||||||||
| 2026-08-01 | 1%(1%) | 0 | 0.8 | 2.3 | 3.5 | |||||||||||
| 2026-07-31 | 2%(1%) | 162.56 | 1.41% | 57 | 53 | 55 | -0.56% | 0.12% | 0 | -0.2 | 1% | 1 | Short | 55% | 2.4 | -2.5 |
| 2026-07-30 | 1%(1%) | 163.48 | 1.42% | 66 | 56 | 26 | -1.67% | 0.06% | 0.3 | -0.2 | 1.2% | 1.2 | Short | 55% | 2.8 | 3.6 |
| 2026-07-29 | 1%(1%) | 166.25 | 1.41% | 97 | 59 | 29 | -0.62% | 0.5% | 1.3 | -0.2 | 0.8% | 1.2 | Wait | 50% | 2.6 | 1.8 |
| 2026-07-28 | 1%(1%) | 167.29 | 1.32% | 117 | 62 | 70 | 2.37% | 0.56% | 1.3 | 0.3 | 1.2% | 0.8 | Wait | 50% | 2.5 | 6.8 |
| 2026-07-27 | 0%(1.3%) | 163.42 | 1.07% | 83 | 47 | 55 | 0.53% | 0.12% | 0.5 | 0 | 0.6% | 0.7 | Long | 55% | 2.1 | -0.5 |
| 2026-07-26 | 1%(1.4%) | 0.4 | 0.8 | 2 | 3 | |||||||||||
| Long is the preferred trading strategy with 55% chance of being right. Improving trend sentiment and positive hourly trend. Wait action is recommended in three scenarios with either high uncertainty or high risk: 1. The trend sentiment and market sentiment are at the opposite directions. 2. Both trend sentiment and market sentiment are positive, but the price level is elevated. 3. Both trend sentiment and market sentiment are negative, but the price level is depressed. In an uptrend, as an investor, you may want to wait for the pullback to open long position. In a downtrend, the price will likely rebound after huge decline. As an investor, you may want to wait for the rebound to exit long position. | ||||||||||||||||
| Market sentiment will accelerate the current trend when both trend sentiment and market sentiment are at the same direction. Market sentiment will generate volatility when it's at the opposite direction of the trend sentiment. News sentiment measures the daily emotion of the market. News sentiment may impact the daily price change while market sentiment is a more stable and consistent moving force. | ||||||||||||||||
| Analysis | ||
| ● Health Care Sector Check-Up: What Analysts Are Saying Right Now Mon. Sep 29, 2025 | ||
| Market News | ||
| 1 (-5) Gilead Swings To Q2 Loss On Acquisition Charges Gilead Sciences Inc. (GILD) on Tuesday reported a second-quarter loss, as more than $11 billion in acquired in-process research and development charges tied to recent acquisitions outweighed double-digit revenue growth. (https://www.rttnews.com/) Tue. Aug 4, 2026 | ||
| 2 (-4) Gilead Swings To Q2 Loss On Acquisition Charges Gilead Sciences Inc. (GILD) on Tuesday reported a second-quarter loss, as more than $11 billion in acquired in-process research and development charges tied to recent acquisitions outweighed double-digit revenue growth. (https://www.rttnews.com/) Tue. Aug 4, 2026 | ||
| 3 (2) Pfizer Covid Pill Revenue Plunges 95%. The Stock Is Rising Anyway. Pfizer beats earnings forecasts for the second quarter, while BioNTech’s results miss expectations due to weak Covid vaccine demand. (https://www.barrons.com/) Tue. Aug 4, 2026 | ||
| 4 (5) Gilead Posts a Loss on Acquisitions but Revenue Tells a Bigger Story Gilead Sciences posts higher revenue as its market-leading HIV drug portfolio continues to drive growth. (https://www.barrons.com/) Tue. Aug 4, 2026 | ||
| 5 (8) Gilead Sales Beat Expectations on Strong HIV Prevention Growth Gilead Sciences Inc. reported sales growth that beat expectations, as its drugs for HIV prevention and treatment continued to perform well. (https://www.bloomberg.com/) Tue. Aug 4, 2026 | ||
| 6 (5) Eli Lilly Could Swing $65.9 Billion After Earnings Earnings coming Wed with varying volatility levels. Benzinga Pro selected list incl. relatively muted setups to double-digit swings. Top pick Eli Lilly. (https://www.benzinga.com/) Tue. Aug 4, 2026 | ||
| 7 (2) Novo Nordisk stock is sliding again — and the Wegovy pill’s surprise miss is partly to blame The Danish drugmaker also revealed an improved outlook for the year. (https://www.marketwatch.com/) Tue. Aug 4, 2026 | ||
| 8 (-2) Novo Nordisk Raises Earnings Guidance. The Stock Sinks. The Danish drugmaker continues to rely on the success of semaglutide, branded as Wegovy for weight loss and Ozempic for diabetes. (https://www.barrons.com/) Tue. Aug 4, 2026 | ||
| 9 (2) Pfizer Covid Pill Revenue Plunges 95%. The Stock Is Rising Anyway. Pfizer beats earnings forecasts for the second quarter, while BioNTech’s results miss expectations due to weak Covid vaccine demand. (https://www.barrons.com/) Tue. Aug 4, 2026 | ||
| 10 (-5) Novo Nordisk shares slide after guidance disappoints investors Novo Nordisk raised its financial outlook as it tries to catch up with rival Eli Lilly in the booming GLP-1 market. (https://www.cnbc.com/) Tue. Aug 4, 2026 | ||
| 11 (2) DuPont Says It Is Exploring M&A Opportunities in Water and Healthcare DuPont Earnings Outlook improves after a Q2 beat, but a narrower sales range and currency headwinds pressure shares. (https://www.benzinga.com/) Tue. Aug 4, 2026 | ||
| 12 (-7) Why Merck Just Slashed Its Profit Outlook By Nearly 50% Merck cuts FY2026 adjusted EPS outlook nearly in half to $2.66-$2.76, citing $2.43/share in charges from its Terns acquisition. (https://www.benzinga.com/) Tue. Aug 4, 2026 | ||
| 13 (-3) Ozempic Maker Novo Nordisk Raises Outlook but Sales Fall on Tough Comparison, Stock Tanks Novo Nordisk raises 2026 guidance as Wegovy pill tops 5 million U.S. prescriptions, but stock falls despite higher GLP-1 sales expectations. (https://www.benzinga.com/) Tue. Aug 4, 2026 | ||
| 14 (6) Merck Stock Rises as Wall Street Looks Past Earnings Guidance Cut to Oncology Strength Merck posts a narrower-than-expected quarterly loss fueled by growth in its oncology segment. (https://www.barrons.com/) Tue. Aug 4, 2026 | ||
| 15 (-3) Pfizer Covid Pill Revenue Plunges 95%. That’s Just One Reason the Stock Is Slipping. Pfizer beats earnings forecasts for the second quarter, while BioNTech’s results miss expectations due to weak Covid vaccine demand. (https://www.barrons.com/) Tue. Aug 4, 2026 | ||
| 16 (8) Novo Nordisk Boosts Forecast on Soaring GLP-1 Sales Novo Nordisk A/S raised its forecast for the second time this year, citing higher expectations for its obesity and diabetes drug sales. (https://www.bloomberg.com/) Tue. Aug 4, 2026 | ||
| 17 (8) Why Is IDEXX Laboratories Stock Gaining Tuesday? IDEXX Laboratories (IDXX) stock rose after reporting Q2 earnings of $4.27/share and $1.22B in revenue, beating Wall Street estimates. (https://www.benzinga.com/) Tue. Aug 4, 2026 | ||
| 18 (8) Pfizer's Diversified Drug Portfolio Fuels Growth as COVID Sales Decline Pfizer stock rises after beating Q2 estimates and raising its 2026 revenue guidance to up to $62.5B. Get the key earnings takeaways. (https://www.benzinga.com/) Tue. Aug 4, 2026 | ||
| 19 (-3) Pfizer Covid Pill Revenue Plunges 95%. That’s Just One Reason the Stock Is Slipping. Pfizer beats earnings forecasts for the second quarter, while BioNTech’s results miss expectations due to weak Covid vaccine demand. (https://www.barrons.com/) Tue. Aug 4, 2026 | ||
| 20 (6) Merck Stock Rises as Wall Street Looks Past Earnings Guidance Cut to Oncology Strength Merck posts a narrower-than-expected quarterly loss fueled by growth in its oncology segment. (https://www.barrons.com/) Tue. Aug 4, 2026 | ||
| 21 (4) Merck Stock Rises as Wall Street Looks Past Earnings Guidance Cut Merck posts a narrower-than-expected quarterly loss fueled by growth in its oncology segment. (https://www.barrons.com/) Tue. Aug 4, 2026 | ||
| 22 (2) Pfizer Covid Pill Revenue Plunges 95%. Why Earnings Are Lifting the Stock Anyway. Pfizer beats earnings forecasts for the second quarter, while BioNTech’s results miss expectations due to weak Covid vaccine demand. (https://www.barrons.com/) Tue. Aug 4, 2026 | ||
| 23 (2) Pfizer Covid Pill Revenue Plunges 95%. Why Earnings Are Lifting the Stock Anyway. Pfizer beats earnings forecasts for the second quarter, while BioNTech’s results miss expectations due to weak Covid vaccine demand. (https://www.barrons.com/) Tue. Aug 4, 2026 | ||
| 24 (7) Merck Stock Rises as Wall Street Looks Past Earnings Guidance Cut Merck posts a narrower-than-expected quarterly loss fueled by growth in its oncology segment. (https://www.barrons.com/) Tue. Aug 4, 2026 | ||
| 25 (3) Merck hikes revenue outlook as new drug sales grow, but cuts profit guidance due to deal charges Merck cut its profit guidance due to a charge tied to its acquisition of biotech company Terns Pharmaceuticals. (https://www.cnbc.com/) Tue. Aug 4, 2026 | ||
| 26 (4) Pfizer tops estimates, hikes low end of revenue guidance on strength of Eliquis, other drugs Pfizer said it cut its full-year revenue expectation for its Covid products to $4 billion, down from around $5 billion previously. (https://www.cnbc.com/) Tue. Aug 4, 2026 | ||
| 27 (7) 3 Healthcare Stocks With Fresh Dividend Hikes and Different Income Profiles McKesson, Encompass Health and Omega Healthcare Investors raised dividends, with payout ratios and yields showing varying levels of sustainability across the healthcare sector. (https://www.marketbeat.com/) Mon. Aug 3, 2026 | ||
| 28 (-3) Bristol Myers Squibb Stock Falls on Report of $400 Billion Merger Talks With AstraZeneca A merger between Bristol Myers Squibb and AstraZeneca would be one of the biggest pharma deals ever. AstraZeneca’s market capitalization stood at $264 billion as of Friday’s close, while Bristol Myers Squibb had a total valuation of $133 billion. (https://www.barrons.com/) Mon. Aug 3, 2026 | ||
| 29 (8) Baxter International Inc. stock outperforms competitors on strong trading day Shares of Baxter International Inc. BAX advanced 7.42% to $28.10 Monday, on what proved to be an all-around favorable trading session for the stock market, with the S&P 500 Index SPX rising 1.48% to 7,600.50 and the Dow Jones Industrial Average DJIA rising 1.32% to 53,178.41. Baxter International Inc. closed 6.33% short of its 52-week high of $30.00, which the company achieved on July 30th. (https://www.marketwatch.com/) Mon. Aug 3, 2026 | ||
| 30 (0) AstraZeneca-Bristol Myers Merger Buzz Puts Patent Expiration and Deal Economics in Focus AstraZeneca and Bristol Myers reportedly discuss a $400 billion merger as analyst assesses valuation, patent risks and regulatory hurdles. (https://www.benzinga.com/) Mon. Aug 3, 2026 | ||
| 31 (8) Analyst Calls Curium's $8 Billion Lantheus Buyout An 'Excellent Outcome' For Shareholders CapVest-backed Curium agrees to acquire Lantheus for up to $8B, expanding its global footprint in nuclear medicine. (https://www.benzinga.com/) Mon. Aug 3, 2026 | ||
| 32 (-6) AstraZeneca Investors See Little Logic in Bristol Tie-Up AstraZeneca Plc investors had a clear message for the UK drugmaker on Monday: they don’t like the idea of a $400 billion merger with Bristol-Myers Squibb Co. (https://www.bloomberg.com/) Mon. Aug 3, 2026 | ||
| 33 (8) Supernus to Combine with Indivior To Form CNS Biopharmaceutical Leader with Potential $2 Billion in Revenue Supernus and Indivior agree to merge in an all-stock deal, targeting $2.2 billion in revenue and $125 million in synergies. (https://www.benzinga.com/) Mon. Aug 3, 2026 | ||
| 34 (8) Integer Shares Rally On $127 Per Share KKR Offer Integer Holdings shares gained after KKR agreed to acquire the medical device company in a transaction valued at approximately $5.7 billion. (https://www.benzinga.com/) Mon. Aug 3, 2026 | ||
| 35 (8) Bristol Myers Squibb Stock Jumps on Report of $400 Billion Merger Talks With Big Rival The merger would be one of the biggest pharma deals ever. AstraZeneca’s market capitalization stood at $264 billion as of Friday’s close, while Bristol Myers Squibb had a total valuation of $133 billion. (https://www.barrons.com/) Mon. Aug 3, 2026 | ||
| 36 (6) KKR to Buy Device Maker Integer in $5.7 Billion Deal KKR has agreed to buy US medical device company Integer Holdings Corp. in an all-cash deal valued at about $5.7 billion. (https://www.bloomberg.com/) Mon. Aug 3, 2026 | ||
| 37 (8) Why Is Bristol-Myers Squibb Stock Surging Monday? Bristol Myers Squibb and AstraZeneca in talks for a $400B mega-merger, potentially creating the world's 4th-largest drugmaker. (https://www.benzinga.com/) Mon. Aug 3, 2026 | ||
About
Contact Us
Copyright ©2025 TheMarketUnfolds. All rights reserved. Denver, Colorado, USA